Login
$ELOX
$12.75 -$0.40 (3.04%) Live

$ELOX 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition

Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; topline data from the 16-week placebo-controlled portion expected in mid-2027

22 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

11 Aug 2026 8-K: Results of Operations and Financial Condition

Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company’s balance sheet

01 Jun 2026 8-K: Unregistered Sales of Equity Securities; Material Modification to Rights of Security Holders +2 more

1. ELOXX PHARMACEUTICALS, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows:

01 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On April 28, 2026 (the “Record Date”), there were 7,573,935 shares of Eloxx Pharmaceuticals, Inc.’s (the “Company”) common stock outstanding and entitled to vote. On April 28, 2026, stockholders holding 4,324,964 shares of common stock (...

12 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

17 Oct 2024 8-K: Departure/Election of Directors or Officers; Compensation

This Amendment to Stock Option Agreement (the “Amendment”) is made as of October 16, 2024 between the undersigned Participant (“Participant”) and Eloxx Pharmaceuticals, Inc. (the “Company”).

16 Jul 2024 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On July 10, 2024 (the “Closing Date”), Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Sixth Amendment (the “Sixth Amendment”) to the Loan and Security Agreement, dated as of September 30, 2021, by and among (i) Hercules Cap...

29 Mar 2024 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 Mar 2024 8-K: Entry into a Material Definitive Agreement

On March 11, 2024, Eloxx Pharmaceuticals, Inc. (the “Company” or “Eloxx”) entered into an exclusive license agreement with Almirall, S.A. (“Almirall”) covering the Company’s asset ZKN-013 (the “License Agreement”). Under the terms of the...

09 Jan 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

On January 9, 2024 (the “Closing Date”), Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fifth Amendment to the Loan and Security Agreement (the “Fifth Amendment”) by and among (i) Hercules Capital, Inc., a Maryland corporat...

28 Dec 2023 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

15 Dec 2023 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On December 15, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fourth Amendment to the Loan and Security Agreement (the “ Fourth Amendment”) by and among (i) Hercules Capital, Inc., a Maryland corporation (“Hercules”)...

13 Nov 2023 8-K: Results of Operations and Financial Condition

Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome

16 Oct 2023 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On October 12, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), received a determination letter (the “Delisting Notification”) from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq ...

20 Sep 2023 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Registration Statement on Form S-3 (No. 333-258994); 305,590 shares of common stock, $0.01 par value per share and pre-funded warrants to purchase up to 75,000 shares of common stock, $0.01 par value per share

18 Sep 2023 8-K: Other Events

Eloxx Pharmaceuticals, Inc. (the “Company”) is providing the following business update.

15 Sep 2023 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

07 Sep 2023 8-K: Other Events

Eloxx Pharmaceuticals, Inc. (the “Company”) is providing the following business update.

29 Aug 2023 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support